Roche may have to up Illumina bid as it extends tender offer
This article was originally published in Scrip
Executive Summary
Roche's hostile takeover attempt of gene sequencing firm Illumina has had a lukewarm response from Illumina's shareholders, forcing Roche to extend its tender offer period. Illumina shareholders now have until 23 March to tender their shares at the unrevised; the offer was previously set to expire on 24 February.